Raymond J. Lanzafame, M.D., M.B.A.; Raymond Blanche; Adam B. Bodian, M.D., et al.
Low level laser therapy (LLLT) has been used to promote hair growth. A double-blind randomised controlled study was undertaken to define the safety and physiologic effects of iGrow® system using Low-Level Laser Therapy on males with androgenic alopecia. 44 males were recruited for the study of 16 weeks.
At the end of 16 weeks, no adverse events or side effects were reported. 41 patients completed the study. (22 laser, 19 placebo). Baseline hair counts were 162.7 ± 95.9 (N=22) in placebo and 142.0 ±73.0 (N= 22) and laser groups respectively (P= 0.426). Post Treatment hair counts were 162.4 ± 62.5 (N= 19) and 228.7 ± 102.8 (N= 22) respectively (P=0.0161). A 39% percent hair increase was demonstrated (28.4 ± 46.2 placebo, N=19; 67.2 ± 33.4, laser, N=22) (P=0.001).
Low-Level Laser Therapy of the scalp with iGrow® device significantly improved hair counts in males with androgenetic alopecia.
Definition: Placebo – a substance with no pharmacological effect but administered as a control in testing experimentally or clinically the efficacy of a biologically active preparation. (Source: Dictionary.com)
ClinicalTrials.gov Identifier: NCT01437163